Post by Aptar

Recent perspectives from Nanopharm Ltd, an Aptar Pharma Company, highlight evolving FDA guidance on NGP pMDIs and their implications for formulation development. These developments support the transition to low-GWP propellants while reinforcing the need for robust, integrated approaches, aligning propellant selection, device compatibility, and aerosol performance to ensure consistency and manufacturability. As regulatory expectations evolve, this added clarity helps pharmaceutical companies move forward with greater confidence while accelerating development and strengthening readiness across both formulation and device considerations. Learn more by reading the full article linked below.